Covidien Announces FDA 510(k) Clearance of the Nellcor™ Bedside SpO2 Patient Monitoring System

<0> CovidienRhonda Luniak, 303-305-2263Vice PresidentR&MS CommunicationsorBruce Farmer, 508-452-4372Vice PresidentPublic RelationsorColeman Lannum, CFA, 508-452-4343Vice PresidentInvestor RelationsorTodd Carpenter, 508-452-4363DirectorInvestor Relations </0>

(NYSE: COV), a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care solutions, today announced the U.S. Food and Drug Administration (FDA) has granted the Company 510(k) clearance to market the Covidien Nellcor Bedside SpO Patient Monitoring System. The new patient monitoring system is now available for sale in the U.S.

The Nellcor Bedside SpO system with OxiMax technology continuously monitors SpO and pulse rate for adult, pediatric and neonatal patients, giving clinicians instant access to comprehensive trending respiratory information. This enables clinicians to detect subtle, yet critical, heart rate and SpO variations earlier and thus address respiratory complications sooner.

"We are pleased to announce the new Covidien Nellcor Bedside SpO Patient Monitoring System is approved for commercial release in the United States," said Robert J. White, President, Respiratory and Monitoring Solutions, Covidien. "Healthcare professionals on the general care floor, and in other lower- acuity areas of the hospital, need critical patient information at their fingertips so they can respond quickly to health threats. By giving them ready access to a patient's respiratory history, the system allows them to focus on delivering efficient, high-quality care, not gathering and managing data."

The Nellcor Bedside SpO Patient MonitoringSystem also features enhanced digital signal processing for precise SpO readings during low perfusion or other challenging conditions that make it difficult to accurately track these patients. Its SatSeconds alarm management technology differentiates between serious and minor events to reduce clinically insignificant oxygen desaturation alarms. The monitor further offers an intuitive, multicolor screen that is easy to read in any light and from many angles. Additionally, hospital technicians can set institutional defaults, replace the battery, perform diagnostics and generally maintain the monitor within the hospital, saving time and resources.

The Nellcor Bedside SpO Patient Monitoring System meets medical electrical equipment safety standards, including IEC 60601-1:2005, and complies with the Restriction of the Use of Certain Hazardous Substances in Electrical and Electronic Equipment (RoHS) directive for products sold in European Economic Area markets.

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2011 revenue of $11.6 billion, Covidien has 43,000 employees worldwide in more than 65 countries, and its products are sold in over 140 countries. Please visit to learn more about our business.

Photos/Multimedia Gallery Available:

Suggested Articles

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Vertex is keeping mum on exact details but, as with the rest of its biopharma peers, is seeing trial disruption due to the COVID-19 pandemic.

Companies including Novartis and Pfizer are contributing to the joint response through actions including the sharing of proprietary compounds